Novo Nordisk A/S’s blockbuster diabetes drug Ozempic cut patients’ risk of dying in a kidney-disease study, the latest research pointing to the medicine’s usefulness in a constellation of disorders.
OPEC+ to Hold Next Month’s Meeting Online Rather Than in ViennaJailed Russian Tycoon Wins UK Ruling to Block $7.5 Billion PayoutMilei Warns Cabinet’s Future Hinges On Argentina Congress VoteCFTC’s Kristin Johnson a Leading Candidate to Be New FDIC ChairU.S.
African State Bank Is Working on Transmission Auction OfficeBayer Fights for Survival as Roundup Lawsuits Burn CashSingapore Air Changes Seatbelt Sign Rules After Fatal TurbulenceSEC Opens the Door for Spot Ether ETFs in Big Crypto VictoryU.S.
Canada Latest News, Canada Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
High-Risk Options Bet on Bond Rally At Risk of Losing MillionsFor at least one Treasury options trader next week’s inflation data could produce either a windfall or a catastrophic loss.
Read more »
US Senate committee investigates pricing of Novo's Ozempic and WegovyExplore stories from Atlantic Canada.
Read more »
US Senate committee investigates pricing of Novo's Ozempic and WegovyExplore stories from Atlantic Canada.
Read more »
U.S. Senate committee investigates pricing of Novo’s Ozempic and WegovySenator Bernie Sanders sent a letter to Novo’s CEO seeking more information on U.S. prices for the two drugs, which are higher than the prices in other countries
Read more »
Barbra Streisand Says Her Ozempic Comment To Melissa McCarthy Was A ‘Compliment’Elyse Wanshel is a reporter for HuffPost, based in New York. She previously worked as a humor/nightlife columnist for the Miami New Times and misses Cuban coffee and croquetas dearly.
Read more »
US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competitionFederal regulators are challenging patents on 20 brand-name drugs, including the blockbuster weight-loss injection Ozempic, in the latest effort by the Biden administration targeting pharmaceutical industry practices that drive up prices.
Read more »